These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 27993663)

  • 1. Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study.
    Tsai HT; Pfeiffer RM; Philips GK; Barac A; Fu AZ; Penson DF; Zhou Y; Potosky AL
    J Urol; 2017 May; 197(5):1251-1257. PubMed ID: 27993663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.
    Magnan S; Zarychanski R; Pilote L; Bernier L; Shemilt M; Vigneault E; Fradet V; Turgeon AF
    JAMA Oncol; 2015 Dec; 1(9):1261-9. PubMed ID: 26378418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).
    Schulman C; Cornel E; Matveev V; Tammela TL; Schraml J; Bensadoun H; Warnack W; Persad R; Salagierski M; Gómez Veiga F; Baskin-Bey E; López B; Tombal B
    Eur Urol; 2016 Apr; 69(4):720-727. PubMed ID: 26520703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
    Nguyen C; Lairson DR; Swartz MD; Du XL
    Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.
    Salonen AJ; Taari K; Ala-Opas M; Viitanen J; Lundstedt S; Tammela TL;
    J Urol; 2012 Jun; 187(6):2074-81. PubMed ID: 22498230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.
    Hershman DL; Unger JM; Wright JD; Ramsey S; Till C; Tangen CM; Barlow WE; Blanke C; Thompson IM; Hussain M
    JAMA Oncol; 2016 Apr; 2(4):453-61. PubMed ID: 26720308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent versus continuous androgen deprivation in prostate cancer.
    Hussain M; Tangen CM; Berry DL; Higano CS; Crawford ED; Liu G; Wilding G; Prescott S; Kanaga Sundaram S; Small EJ; Dawson NA; Donnelly BJ; Venner PM; Vaishampayan UN; Schellhammer PF; Quinn DI; Raghavan D; Ely B; Moinpour CM; Vogelzang NJ; Thompson IM
    N Engl J Med; 2013 Apr; 368(14):1314-25. PubMed ID: 23550669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials.
    Niraula S; Le LW; Tannock IF
    J Clin Oncol; 2013 Jun; 31(16):2029-36. PubMed ID: 23630216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
    Keating NL; O'Malley AJ; Freedland SJ; Smith MR
    J Natl Cancer Inst; 2010 Jan; 102(1):39-46. PubMed ID: 19996060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
    Keating NL; O'Malley AJ; Smith MR
    J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer.
    Schmid M; Hanske J; Ravi P; Krishna N; Reznor G; Meyer CP; Fisch M; Noldus J; Nguyen PL; Trinh QD
    Int J Urol; 2016 Apr; 23(4):305-11. PubMed ID: 26763083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.
    Gillessen S; Templeton A; Marra G; Kuo YF; Valtorta E; Shahinian VB
    J Natl Cancer Inst; 2010 Dec; 102(23):1760-70. PubMed ID: 21068432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects.
    Salonen AJ; Taari K; Ala-Opas M; Viitanen J; Lundstedt S; Tammela TL;
    Eur Urol; 2013 Jan; 63(1):111-20. PubMed ID: 22857983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.
    Sari Motlagh R; Quhal F; Mori K; Miura N; Aydh A; Laukhtina E; Pradere B; Karakiewicz PI; Enikeev DV; Deuker M; Shariat SF
    J Urol; 2021 Jan; 205(1):60-67. PubMed ID: 32856962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen Deprivation Therapy Use Increases the Risk of Heart Failure in Patients With Prostate Cancer: A Population-Based Cohort Study.
    Kao HH; Kao LT; Li IH; Pan KT; Shih JH; Chou YC; Wu ST
    J Clin Pharmacol; 2019 Mar; 59(3):335-343. PubMed ID: 30402905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.
    Abrahamsson PA
    Eur Urol; 2010 Jan; 57(1):49-59. PubMed ID: 19683858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
    Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
    Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.